TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10397651
Drug: TPS cylinder
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TPS cylinder implants
Study: 28704492
Drug: Pretreatment MMP9
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pretreatment MMP9 levels in CSF (median [interquartile range], 254 [115‐389] ng/mL in good outcome group)
Study: 28704492
Drug: Pretreatment MMP9
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pretreatment MMP9 levels in CSF (median [interquartile range], 192 [60‐383] ng/mL in poor outcome group)
Study: 28704492
Drug: TIMP1 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIMP1 levels in CSF (1239 [889‐1511] ng/mL in good outcome group)
Study: 28704492
Drug: TIMP1 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIMP1 levels in CSF (1522 [934‐1949] ng/mL in poor outcome group)
Study: 8224655
Drug: Propranolol (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (continuous administration to reduce resting heart rate by 25%)
Study: 8224655
Drug: Sclerotherapy (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy (weekly intravariceal sessions using 5% ethanolamide oleate until varices disappeared)
Study: 26881516
Drug: Concomitant boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant boost therapy with cisplatin (Arm B)
Study: 16870801
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acid supplementation as an adjunct to standard pharmacotherapy
Study: 15295717
Drug: Candesartan 16
Normalized name: candesartan 16 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan 16 mg + Lisinopril 20 mg
Study: 11738913
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation of betamethasone and neomycin eyedrops
Study: 15102426
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (ibuprofen, paracetamol, placebo)
Study: 2680896
Drug: Metronidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (2 g twice at an interval of two days)
Study: 2680896
Drug: Placebo (inert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inert but identical tablets)
Study: 22238470
Drug: Miltefosine (1.8‐2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine (1.8‐2.5 mg/kg/d for 28 days; by mouth)
Study: 22238470
Drug: Meglumine antimoniate
Normalized name: meglumine antimoniate
DrugBank: Meglumine antimoniate (DB13732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meglumine antimoniate (20 mg Sb/kg/d for 20 days; intramuscular)
Study: 20921440
Drug: Perhexiline 100
Normalized name: perhexiline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perhexiline 100 mg (n=24)
Study: 10618544
Drug: Engerix-B 10
Normalized name: Engerix-B 10 MCG per 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B 10 microg vaccine (EB)
Study: 9093239
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment and therapy for opportunistic infections
Study: 9093239
Drug: HIV-associated non-Hodgkin
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-associated non-Hodgkin lymphomas treatment
Study: 9093239
Drug: HIV-associated central
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-associated central nervous system lymphomas treatment
Study: 9093239
Drug: Hodgkin's disease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hodgkin's disease treatment in HIV-infected individuals
Study: 8292067
Drug: Enteric coated
Normalized name: Mesasal Enteric Coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated multiple-unit formulation (Diclo-Puren 50)
Study: 8292067
Drug: Single-unit dosage
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-unit dosage form (reference)
Study: 2880294
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 mg per kilogram of body weight per day) with decongestant-antihistamine
Study: 2880294
Drug: Amoxicillin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (40 mg per kilogram of body weight per day) without decongestant-antihistamine
Study: 29087443
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment included in the programme (Group A)
Study: 29087443
Drug: Usual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatment plus attendance at self-help groups (Group B)
Study: 16419568
Drug: SPECT scans
Normalized name: spelt seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: SPECT scans after i.v. injection of 99mTc‐ECD of 0.3 mCi/kg b.m.
Study: 12591833
Drug: Subcutaneous dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dalteparin twice daily for three months
Study: 2882776
Drug: Carteolol (beta-adrenoceptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carteolol (beta-adrenoceptor blocker)
Study: 29072044
Drug: Focused shock
Normalized name: house dust allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused shock wave therapy
Study: 25539757
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) + olanzapine (5 mg/day) for 3 months
Study: 19212708
Drug: Docetaxel (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (45 mg/m²) combined with 5‐FU/leucovorin
Study: 19212708
Drug: Irinotecan (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (180 mg/m²) combined with 5‐FU/leucovorin
Study: 12500022
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg once daily)
Study: 15829533
Drug: Daily budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily budesonide therapy
Study: 15829533
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment with budesonide
Study: 15829533
Drug: Daily zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily zafirlukast therapy
Study: 9282581
Drug: Enalapril in
Normalized name: enalapril Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril in combination with bronchodilators, diuretics, antibiotics and/or steroids
Study: 9282581
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with diuretics, steroids and antibiotics alone
Study: 1713663
Drug: Morphine 5
Normalized name: ethylmorphine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 5 mg via epidural administration
Study: 1713663
Drug: Hydromorphone 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 0.75 mg via epidural administration
Study: 24711552
Drug: Exemestane (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane (25 mg per day)
Study: 20329618
Drug: Zengjing Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zengjing Capsule No. 1 (ZJC1)
Study: 17259038
Drug: Breast-feeding before,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-feeding before, during, and after the injection
Study: 2658640
Drug: Cefuroxime 1
Normalized name: cefuroxime 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime 1 g
Study: 51285
Drug: Bromocriptine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (mean 46.9 mg daily)
Study: 26488347
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg/day (non-bulimic patients)
Study: 17146981
Drug: Adaptive allocation
Normalized name: ADAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive allocation treatment
Study: 11256775
Drug: Dalteparin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (120 IU/kg twice daily)
Study: 9167318
Drug: Fluvoxamine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine plus cognitive behaviour therapy
Study: 9167318
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cognitive behaviour therapy
Study: 9167318
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy alone
Study: 8245990
Drug: Warfarin anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin anticoagulation (6-12 weeks course)
Study: 31978933
Drug: MDMA (0.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA (0.75, 1.5 mg/kg)
Study: 24448644
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (20 or 40 IU)
Study: 23140055
Drug: Medication (Ranitidine)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Ranitidine)
Study: 23140055
Drug: Medication (Ranitidine)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Ranitidine) (1 month follow-up)
Study: 12552508
Drug: N-acetylcysteine (NAC),
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC), 1.2 g twice a day for 4 weeks
Study: 10651655
Drug: Eudragit-coated gelatine
Normalized name: Gelatin
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eudragit-coated gelatine capsule containing 111In-labelled amberlite resin
Study: 9007589
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg on the first day then 200 mg)
Study: 9007589
Drug: Amphotericin B/5-flucytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphotericin B/5-flucytosine (1.0-1.5 mg/kg body weight every other day and 3 x 2.5 g flucytosine/day)
Study: 6094438
Drug: Cefotaxime (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (50 mg/kg/dose every 6 h for 10 to 14 days)
Study: 6094438
Drug: Ampicillin and
Normalized name: Ampicillin and sulbactam only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin and chloramphenicol (standard doses)
Study: 31362183
Drug: Oxytocin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (24 IU intranasal application)
Study: 21294410
Drug: Single-injection paravertebral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-injection paravertebral block (PVB) with 0.3 ml/kg of 0.5% plain bupivacaine at T4 paravertebral space followed by general anesthesia
Study: 18021336
Drug: Praziquantel 20
Normalized name: PRAZIQUANTEL 20 kg in 20 kg POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 20 mg/kg alone
Study: 18021336
Drug: Praziquantel 20
Normalized name: PRAZIQUANTEL 20 kg in 20 kg POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel 20 mg/kg with ketoconazole 400 mg daily for 5 days
Study: 11911101
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution intake during labour
Study: 9866670
Drug: Recommended levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended levels of antidepressant treatment (doses recommended by the Agency for Health Care Policy and Research for 90 days or more)
Study: 9866670
Drug: Less-than-recommended levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less-than-recommended levels of antidepressant treatment
Study: 9866670
Drug: Minimum recommended
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum recommended levels of antidepressant treatment
Study: 7533825
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) - lenograstim 5 micrograms/kg/d between cycles
Study: 7533825
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - VICE chemotherapy alone
Study: 26884620
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil (0.2 mg/kg bolus followed by 0.2 mg/kg/h for 24 h)
Study: 11888823
Drug: Iodixanol (320mgI.ml(‐1))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (320mgI.ml(‐1))
Study: 11888823
Drug: Iopromide (300mgI.ml(‐1))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iopromide (300mgI.ml(‐1))
Study: 9598509
Drug: Pretreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretreatment with a gonadotropin‐releasing hormone agonist for 3 months before radical prostatectomy
Study: 7934431
Drug: Sumatriptan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (16 mg, subcutaneous administration)
Study: 3793199
Drug: Domperidone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (0.3 mg/kg)
Study: 26004393
Drug: S-1 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 administration for more than 1 year
Study: 26004393
Drug: S-1 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 administration periods of 24 months or longer
Study: 26004393
Drug: S-1 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 administration
Study: 19307517
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D (with or without calcium)
Study: 19307517
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of oral vitamin D (>400 IU/d)
Study: 16870768
Drug: Tefibazumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tefibazumab (20 mg/kg as a single infusion)
Study: 14997746
Drug: Breast conservation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conservation treatment
Study: 14997746
Drug: Breast conservation
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast conservation treatment in ductal carcinoma in situ
Study: 9476185
Drug: Ranitidine, prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, prescribed to 73.9% of patients receiving treatment.
Study: 9476185
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment motivated by fear of stress mucosal lesions (28%) and therapy with other drugs (56%).
Study: 9476185
Drug: General prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: General prescription practices for peptic diseases.
Study: 2959623
Drug: GTF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTF vaccine with aluminum phosphate (AP)
Study: 24731231
Drug: Exogenous glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous glutamine supplementation (L-alanyl-L-glutamine, 0.28 g/kg during 20 hours)
Study: 18940387
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol gel
Study: 2481772
Drug: Nicardipine (NIC)
DrugBank: Nicardipine (DB00622)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicardipine (NIC) 20 mg t.i.d.
Study: 2481772
Drug: Captopril (CAP)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CAP) 50 mg b.i.d.
Study: 23098686
Drug: AZD9164 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9164 100 μg
Study: 23098686
Drug: AZD9164 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9164 400 μg
Study: 23098686
Drug: AZD9164 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9164 1200 μg
Study: 21421502
Drug: Urokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase and argatroban administered regionally via small saphenous vein catheter
Study: 21421502
Drug: Urokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase and argatroban administered via peripheral vein (control)
Study: 16893433
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg t.i.d. for 12 weeks
Study: 15330957
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural morphine 0.1 mg x kg(‐1) in 0.2 ml x kg(‐1) saline (TEP group, n = 16)
Study: 15330957
Drug: Morphine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine infusion at 0.02 mg x kg(‐1) h(‐1) (INF group, n = 16)
Study: 9009045
Drug: Exposure with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure with response prevention (standard behavior therapy protocol including in vivo and imagery exposure)
Study: 8390952
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interferon alfa‐2b (6 million units)
Study: 8390952
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose interferon alfa‐2b (3 million units)
Study: 24685847
Drug: Methotrexate 15
Normalized name: methotrexate 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 15 mg weekly for 12 weeks
Study: 8958191
Drug: Cilazapril (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (1 mg/day)
Study: 1286486
Drug: Etodolac 600
Normalized name: etodolac 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 600 mg/day
Study: 3927650
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg L-Deprenyl per day
Study: 3927650
Drug: L-Deprenyl
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Deprenyl
Study: 29688628
Drug: Verinurad 10
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 10 mg + Febuxostat 40 mg
Study: 29688628
Drug: Verinurad 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad 2.5 mg + Febuxostat 80 mg
Study: 29688628
Drug: Verinurad and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad and Febuxostat combination
Study: 29314344
Drug: Intensive fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive fluoride varnish treatment (three applications within 2 weeks and additional applications at 1 and 3 months)
Study: 29314344
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (semi-annual fluoride varnish treatment)
Study: 10102764
Drug: Citicoline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline (500 mg bid)
Study: 7778430
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol for 12 weeks
Study: 17459479
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of intravitreal triamcinolone (TA)
Study: 17459479
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of intravitreal triamcinolone (TA) combined with sequential grid laser
Study: 14717388
Drug: Beta-blockers in
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers in addition to digoxin, diuretics, and ACE inhibitors
Study: 11115031
Drug: Early home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early home-based intervention with weekly home visits from a child health nurse for 6 weeks, then fortnightly visits to 3 months, with some receiving short-term dynamic therapy from a social worker.
Study: 9190006
Drug: Floctafenin, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floctafenin, 800 mg/day
Study: 9190006
Drug: Acetaminophen, 3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen, 3000 mg/day
Study: 1541877
Drug: Warfarin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin as an adjuvant to standard treatment
Study: 1541877
Drug: Warfarin enantiomers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin enantiomers (R,S) analysis
Study: 1541877
Drug: Warfarin disposition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin disposition
Study: 3020703
Drug: Sequential hemibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential hemibody radiotherapy
Study: 31322496
Drug: Peripheral blood
Normalized name: Peripheral blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral blood mononuclear cells (PBMC) transfer; 0.4 ml of cultured PBMCs transferred into the uterus two days prior to embryo transfer
Study: 31229622
Drug: GEM intervention
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEM intervention (tablet-delivered goal setting tool, health coaching visit, twelve telephone calls, provider counseling training)
Study: 24322191
Drug: Fresh cheese
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh cheese enriched with Bifidobacterium lactis Bi‐07 (30 g/day for 30 days)
Study: 24322191
Drug: Regular fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular fresh cheese (30 g/day for 30 days)
Study: 10773903
Drug: Mega-dose capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mega-dose capsule distribution
Study: 21739240
Drug: Modified-policosanol (MP)
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-policosanol (MP) 20 mg daily with background statin therapy
Study: 21739240
Drug: Modified-policosanol (MP)
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-policosanol (MP) 20 mg daily as monotherapy
Study: 21739240
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with background statin therapy
Study: 17024505
Drug: Ertapenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertapenem (1 g daily)
Study: 17024505
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g every 12 h with optional metronidazole 500 mg every 12 h)
Study: 15219514
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of autologous bone marrow mesenchymal stem cell
Study: 11174623
Drug: First-phase insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-phase insulin release during IV-GTT
Study: 8501503
Drug: VCMP/VBAP combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCMP/VBAP combination chemotherapy